DAM
NVS icon

Deimos Asset Management’s Novartis NVS Stock Holding History

Deimos Asset Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-20,869
Closed -$1.61M – 138
2015
Q4 		$1.61M Buy
+20,869
New +$1.66M 0.97% 28

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Deimos Asset Management's NVS Position: Q1 2016 in Review

Deimos Asset Management sold out of Novartis (NVS) in Q1 2016, closing a stake of 20,869 shares — an estimated $1.61M sold.

Deimos Asset Management first reported a position in NVS in Q4 2015 and held it in 1 quarter. The position peaked at $1.61M in Q4 2015. 875 funds tracked by Wall St. Rank hold NVS as of Q1 2016.

  • Deimos Asset Management reported no remaining Novartis position as of Q1 2016 after selling out during the quarter.
  • Deimos Asset Management sold 20,869 Novartis shares in Q1 2016, an estimated $1.61M.
  • Deimos Asset Management first reported a position in Novartis in Q4 2015 and held it in 1 quarter.
  • Deimos Asset Management's Novartis position peaked at $1.61M in Q4 2015.
  • 875 funds tracked by Wall St. Rank held Novartis as of Q1 2016.

Based on Deimos Asset Management's 13F filing for Q1 2016, filed 13 May 2016.